tbuckley/cabot-search huggingface dataset:
Abstract 303: Exercise-induced Autophagy and Nadph Oxidase 2 Downregulation Prevents Cardiotoxicity Induced by Doxorubicin
Authors: Youngil Lee, Insu Kwon, Yongchul Jang, Ludmila Cosio-Lima
Journal: Circulation Research (2019)

Endurance exercise (EXE) preconditioning prior to DOX treatment confers cardioprotection; however, whether EXE postconditioning (i.e., EXE intervention after the completion of DOX treatment) is cardioprotective remains unknown. Thus, the aim of the present study was to investigate if EXE postconditioning provide cardioprotection by testing the hypothesis that EXE-autophagy upregulation and NADPH oxidase 2 (NOX2) downregulation would be linked to cardioprotection against DOX-induced cardiotoxicity. C57BL/6 male mice were assigned into three groups: control (CON, n=10), doxorubicin (DOX, n=10), and doxorubicin + endurance exercise (DOX+EXE, n=10). Animals assigned to DOX and DOX+EXE groups were intraperitoneally injected with DOX (5 mg/kg each week for four weeks). 48 hours after the last DOX treatment, the mice assigned to DOX+EXE performed EXE on a motorized treadmill at a speed of 13-15 m/min for 60 min per day for four weeks. EXE prevented DOX-induced apoptosis and mitigated tissue damages. While DOX did not modulate auto/mitophagy, EXE significantly enhanced its flux (increased LC3-II levels, reduced p62 levels, and increased autophagosomes with mitochondria) along with increased mitochondrial fission (DRP1) and reduced fusion markers (OPA1 and MFN2). Interestingly, EXE-induced autophagy against DOX occurred in the absence of alterations of autophagy inducer AMPK or autophagy inhibitor mTOR signaling. EXE prohibited DOX-induced oxidative damages by suppressing NOX2 levels but without modulating other key antioxidant enzymes including MnSOD, CuZnSOD, CATALSE, and GPX1/2. Our data provide novel findings that EXE-induced auto/mitophagy promotion and NOX2 downregulation are linked to cardioprotection against DOX-induced cardiotoxicity. Importantly, our study shows that EXE postconditioning intervention is effective and efficacious to prevent DOX-induced cardiac injuries.
When You Can’t Find a Heartbeat
Authors: Becky J. Buelow, Matthew W. Buelow
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Flow Cytometric Measurement of the Initial In Vivo Response to Prednisone Provides New Prognostic Information in Childhood Acute Lymphoblastic Leukemia (ALL)
Authors: Giuseppe Gaipa, Oscar Maglia, Simona Sala, Noemi Marino, Daniela Silvestri, Maria Grazia Valsecchi, Andrea Biondi, Valentino Conter
Journal: Blood (2018)
A Newcomer's Guide to Functional Near Infrared Spectroscopy Experiments
Authors: Rand K. Almajidy, Kunal Mankodiya, Mohammadreza Abtahi, Ulrich G. Hofmann
Journal: IEEE Reviews in Biomedical Engineering (2019)

This review presents a practical primer for functional near-infrared spectroscopy (fNIRS) with respect to technology, experimentation, and analysis software. Its purpose is to jump-start interested practitioners considering utilizing a non-invasive, versatile, nevertheless challenging window into the brain using optical methods. We briefly recapitulate relevant anatomical and optical foundations and give a short historical overview. We describe competing types of illumination (trans-illumination, reflectance, and differential reflectance) and data collection methods (continuous wave, time domain and frequency domain). Basic components (light sources, detection, and recording components) of fNIRS systems are presented. Advantages and limitations of fNIRS techniques are offered, followed by a list of very practical recommendations for its use. A variety of experimental and clinical studies with fNIRS are sampled, shedding light on many brain-related ailments. Finally, we describe and discuss a number of freely available analysis and presentation packages suited for data analysis. In conclusion, we recommend fNIRS due to its ever-growing body of clinical applications, state-of-the-art neuroimaging technique and manageable hardware requirements. It can be safely concluded that fNIRS adds a new arrow to the quiver of neuro-medical examinations due to both its great versatility and limited costs.
Navigating oncology inpatient care from admission to discharge: A quality improvement study.
Authors: Erin Lightheart, Colleen Kucharczuk
Journal: Journal of Clinical Oncology (2019)

76 Background: Ensuring successful transitions between inpatient and outpatient settings is key in providing quality oncology care. To this aim, our team of inpatient Advanced Practice Providers (APP) recognized that critical components of discharge planning were often left to the provider’s memory, leading to errors, omissions, and inefficiencies. After brainstorming a number of possible quality improvement interventions, the clear choice for a high-impact, low-effort solution was the development of a comprehensive discharge checklist, a tool which has been shown in the literature to be effective in similar settings. Methods: Based on best practice recommendations by the Society of Hospital Medicine regarding key considerations for planning safe discharges, a multidisciplinary group developed a comprehensive discharge document housed within the electronic record, to be initiated at the point of admission and updated continually by both providers and discharge coordinators. The document is not simply a list of tasks, but rather, a comprehensive navigator which guides care throughout the entire inpatient stay. Providers are prompted to consider individualized care critical to timely discharge, such as early administration of blood or electrolytes. We have maintained 100% compliance with utilizing the navigator since its inception. Results: Results are summarized in the table below. Conclusions: What started as a discharge checklist grew into a comprehensive navigator, guiding inpatient oncology care from admission through discharge, and into the outpatient setting. Ultimately, it has improved communication and collaboration among providers, CRCs, nursing, physical therapy, social work, and inpatient and outpatient pharmacy. We believe this systematic approach to the discharge process is applicable in any inpatient setting with any patient population. [Table: see text]
Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ
Authors: Marisa Peluso, Kerrie Faia, David Winkler, Nidhi Patel, Erin Brophy, Kerry White, Mark Douglas, Howard M. Stern, Vito Palombella, Karen McGovern, Jeffery L. Kutok
Journal: Blood (2014)
Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results.
Authors: Robert Z. Orlowski, Keith Stewart, Marcy Vallone, Chris Molineaux, Lori Kunkel, John Gericitano, Owen A. O’Connor
Journal: Blood (2007)
Association of viruses causing acute respiratory infections with meteorological factors and air pollutants in hospitalised children in Macao: a retrospective analysis
Authors: Cheng Lei, Fan Yang, Cheong Tat Lou, Lisong Yang, Kin Ian Si Tou, King Io, Kun Tat Cheok, Hao Hu, Carolina Oi Lam Ung
Journal: The Lancet (2019)
Dengue NS2A Protein Orchestrates Virus Assembly
Authors: Xuping Xie, Jing Zou, Xianwen Zhang, Yiyang Zhou, Andrew L. Routh, Congbao Kang, Vsevolod L. Popov, Xinwen Chen, Qing-Yin Wang, Hongping Dong, Pei-Yong Shi
Journal: Cell Host & Microbe (2019)
Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data
Authors: Katharine J Looker, Nicky J Welton, Keith M Sabin, Shona Dalal, Peter Vickerman, Katherine M E Turner, Marie-Claude Boily, Sami L Gottlieb
Journal: The Lancet Infectious Diseases (2019)

A 2017 systematic review and meta-analysis of 55 prospective studies found the adjusted risk of HIV acquisition to be at least tripled in individuals with herpes simplex virus type 2 (HSV-2) infection. We aimed to assess the potential contribution of HSV-2 infection to HIV incidence, given an effect of HSV-2 on HIV acquisition.
Orphan drugs—access and unmet needs in 194 countries and six regions: a comprehensive policy review with content analysis
Authors: Adrienne Y L Chan, Vivien K Y Chan, Sten Olsson, Min Fan, Mark Jit, Mengchun Gong, Shuyang Zhang, Mengqin Ge, Swathi Pathadka, Celine S L Chui, Esther W Chan, Claudia C Y Chung, Brian H Y Chung, Gloria H Y Wong, Patrick Ip, Terry Y Lum, Ian C K Wong, Xue Li
Journal: The Lancet (2019)
Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509
Authors: Domenico Russo, Giuliana Alimena, Chiara Colombi, Massimo Breccia, Simona Soverini, Ilaria Iacobucci, Federica Cattina, Giovanni Martinelli, Nicoletta Testoni, Anna Marina Liberati, Viviana Appolloni, Mario Tiribelli, Renato Fanin, Felicetto Ferrara, Mario Annunziata, Elena Trabacchi, Daniele Vallisa, Antonio De Vivo, Fausto Castagnetti, Miriam Fogli, Sandra Durante, Francesco Di Raimondo, Fabio Stagno, A. M. Carella, G. Pica, Alessandra Iurlo, Tommaso Radice, Patrizia Pregno, Umberto Vitolo, Elisabetta Abruzzese, Paolo de Fabritiis, Maurizio Longinotti, Simonetta Pardini, Caterina Musolino, Sabina Russo, Marco Gobbi, Ivana Pierri, Gianluca Gaidano, Monia Lunghi, Giuseppe Visani, Sara Barulli, Mario Cazzola, Serena Merante, Cristina Skert, Michele Malagola, Gianantonio Rosti, Michele Baccarani
Journal: Blood (2011)
Botanical Alkyl Hydroquinone Derivative HQ17(3) Induces Calcium-Associated Mitochondrial Damage and Mitophagy to Exert Ctotoxicity to Philadelphila Chromosome(+) ALL Cells
Authors: Yin-Chen Chou, Chia-Wei Chen, Yuan-Yeh Kuo, Liang-In Lin, Chung-Yi Hu
Journal: Blood (2018)
WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil
Authors: Elvira DRP Velloso, Maria Gabriella Cordeiro, Danielle Lucon, Renata Kishimoto, Aline Medeiros Leal, Ana Carolina Arrais Maia, Valeria Buccheri, Israel Bendit, Wellington Fernandes Silva, Cristovao Mangueira, Eduardo Magalhães Rego, Vanderson Rocha
Journal: Blood (2018)
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
Authors: Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong Liu
Journal: Acta Pharmaceutica Sinica B (2019)

Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment. However, most of currently used VEGFR2 kinase inhibitors are multi-target inhibitors which might result in target-associated side effects and therefore limited clinical toleration. Highly selective VEGFR inhibitors are still highly demanded from both basic research and clinical application point of view. Here we report the discovery and characterization of a novel VEGFR2 inhibitor (CHMFL-VEGFR2-002), which exhibited high selectivity among structurally closed kinases including PDGFRs, FGFRs, CSF1R, etc. CHMFL-VEGFR2-002 displayed potent inhibitory activity against VEGFR2 kinase in the biochemical assay (IC50 = 66 nmol/L) and VEGFR2 autophosphorylation in cells (EC50s ∼100 nmol/L) as well as potent anti-proliferation effect against VEGFR2 transformed BaF3 cells (GI50 = 150 nmol/L). In addition, CHMFL-VEGFR2-002 also displayed good anti-angiogenesis efficacy in vitro and exhibited good in vivo PK (pharmacokinetics) profile with bioavailability over 49% and anti-angiogenesis efficacy in both zebrafish and mouse models without apparent toxicity. These results suggest that CHMFL-VEGFR2-002 might be a useful research tool for dissecting new functions of VEGFR2 kinase as well as a potential anti-angiogenetic agent for the cancer therapy.
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
Authors: Saranya Chumsri, Zhuo Li, Daniel J. Serie, Afshin Mashadi-Hossein, Gerardo Colon-Otero, Nan Song, Katherine L. Pogue-Geile, Patrick G. Gavin, Soonmyung Paik, Alvaro Moreno-Aspitia, Edith A. Perez, E. Aubrey Thompson
Journal: Journal of Clinical Oncology (2019)

Recent trials have shown potential benefit of extended adjuvant endocrine therapy and relatively high risk of recurrence (RoR) after 5 years in hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Although risk of late relapse in HR+ HER2- breast cancer is fairly well defined, the risk in HER2-positive (HER2+) breast cancer treated with adjuvant trastuzumab-based chemotherapy remains largely unknown.We included 3,177 patients with HER2+ breast cancer treated with adjuvant chemotherapy alone or with trastuzumab from the North Central Cancer Treatment Group N9831 (ClinicalTrials.gov identifier: NCT00005970) and National Surgical Adjuvant Breast and Bowel Project B-31 (ClinicalTrials.gov identifier: NCT00004067) trials.Overall, HR+ breast cancer was significantly associated with improved recurrence-free survival (RFS) during the first 5 years (hazard ratio, 0.65; 95% CI, 0.56 to 0.77; P < .001). Among patients treated with trastuzumab, cumulative hazard for RFS was lower in patients with HR+ HER2+ breast cancer during the first 5 years (10.96% v 17.48%; hazard ratio, 0.60; 95% CI, 0.45 to 0.79; P < .001). However, there was no significant difference in RFS based on HR status during years 5 to 10 (hazard ratio, 1.32; 95% CI, 0.93 to 1.88; P = .12). A comparable degree of trastuzumab benefit was observed in HR+ and HR- breast cancers ( P for interaction = .87). Furthermore, we observed low RoR in years 5 to 10 among patients with HR+ HER2+ breast cancer: 3.23% in patients without lymph node involvement (N0) and 6.39% in patients with involvement of one to three lymph nodes (N1).The benefit of adjuvant trastuzumab persists for a long time. A distinct pattern of recurrence was observed between HR+ and HR- HER2+ disease but with similar degree of benefit from adjuvant trastuzumab. RoR in years 5 to 10 in HR+ HER2+ breast cancer is low, particularly in patients with N0 or N1 disease.
Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy
Authors: Rebecca Gardner, Olivia Finney, Hannah Brakke, Stephanie Rhea, Roxana Hicks, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, Daniel Li, Michael C. Jensen
Journal: Blood (2018)
Leukemic Blasts Acting as Host Antigen Presenting Cells Trigger a Combined CD4 and CD8 Allo-Immune Response Directed Against Mismatched HLA Class I.
Authors: Avital Amir, Renate S. Hagendoorn, Erik W.A. Marijt, Roelof Willemze, J.H. Frederik Falkenburg, Mirjam Heemskerk
Journal: Blood (2007)
Abstract 333: Cardiomyocyte Hypercontractility is an Adaptational Response to Stiffness in High-Fat Diet Mice
Authors: Johannes V Janssens, Antonia J Raaijmakers, Parisa Koutsifeli, Kimberley M Mellor, Claire L Curl, Lea M Delbridge
Journal: Circulation Research (2019)

Diabetic heart disease typically features a restrictive/ hypertrophic cardiac phenotype characterised by diastolic dysfunction with preserved systolic performance. Little is known about the early adaptational mechanisms that underpin maintenance of systolic performance in diabetic diastolic dysfunction and how this may contribute to disease progression. This study aimed to evaluate cardiomyocyte contractility in a high-fat diet (HFD) mouse model of diastolic dysfunction. Echocardiography (GE Vivid 9) was performed in 33 wk old male C57Bl/6 mice fed a high-fat diet (HFD, 43% kcal fat, 24 wks duration). Isolated cardiomyocytes (paced 2Hz, 2.0mM Ca 2+ , 37C) were subjected to progressive axial stretch. Sarcomere length/ shortening, tension and intracellular calcium transients (Fura-2AM, 5μM) were simultaneously measured (Myostretcher, Ionoptix). HFD hearts displayed in vivo (22.2±1.4 vs 16.7±1.0 E/E’; p&lt;0.05) and in vitro diastolic dysfunction (0.244±0.039 vs 0.075±0.017 nN/pl/ %cell stretch; p&lt;0.05). HFD cardiomyocytes exhibited length-dependent hypercontractility with augmented developed tension amplitude at maximal stretch (4.891±0.942 vs 2.484±0.677 nN/pl; p&lt;0.05), but not basal stretch. Hypercontractility could not be attributed to a difference in Ca 2+ transient amplitude but was correlated with length dependence of Ca 2+ sensitivity (n=17 cells, R 2 =0.4039 p&lt;0.05). During progressive cardiomyocyte stretch, systolic tension slopes were strongly correlated with diastolic tension slopes (cardiomyocyte stiffness) (n=30 cells; R 2 =0.8442, p&lt;0.05) while there was no difference in the ratio of systolic/diastolic tension slopes indicating maintained length-dependent activation. These findings provide the first evidence that cardiomyocyte hypercontractility and stiffness are strongly linked. High-fat diet cardiomyocytes may operate near maximal contractile capacity to maintain basal cardiac output, potentially limiting capacity for cardiac output increase in response to physiological stressors. An aberrant myofilament post-translational modification profile represents a potential mechanism through which cardiac dysfunction arises during the development of diabetes.
Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.
Authors: Valentino Conter, André Schrauder, Helmut Gadner, Maria Grazia Valsecchi, Martin Zimmermann, Michael Dvorzak, Andrea Biondi, Claus R. Bartram, Giuseppe Basso, Martin Stanulla, Maurizio Aricò, Karl Welte, Giuseppe Masera, Martin Schrappe
Journal: Blood (2007)
Full-thickness resection of neuroendocrine tumors in the rectum
Authors: Benjamin Meier, Heinz Albrecht, Thomas Wiedbrauck, Arthur Schmidt, Karel Caca
Journal: Endoscopy (2019)

Abstract Background Rectal neuroendocrine tumors (NETs) are subepithelial tumors with potential for malignancy. Depending on tumor characteristics, endoscopic or surgical resection is recommended. However, the optimal endoscopic approach is not defined. This is the first larger study evaluating endoscopic full-thickness resection (EFTR) of rectal NETs. Methods For resection, the full-thickness resection device (FTRD) was used. A registry was created as part of post-market clinical follow-up. All cases of rectal NETs in the registry were analyzed retrospectively. Results 31 German centers entered data of 501 FTRD procedures and 40 cases of rectal NETs were identified. The median lesion size was 8 mm. All lesions could be resected using FTRD. The median procedure time was 18.5 minutes. Resection was macroscopically and histologically complete in all cases. Full-thickness resection was achieved in 95 %. No major adverse events occurred. Endoscopic follow-up showed no evidence of residual or recurrent tumor. Conclusion EFTR is safe and effective for resection of smaller rectal NETs. Prospective comparative trials are needed to define the role of EFTR of rectal NETs.
JAK3, JAK2 and GATA1 Mutations in Childhood Acute Megakaryoblastic Leukemia with and without Down Syndrome.
Authors: Asahito Hama, Hiroshi Yagasaki, Hideki Muramatsu, Nobuhiro Nishio, Nao Yoshida, Yoshiyuki Takahashi, Seiji Kojima
Journal: Blood (2007)
Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California
Authors: Nicolas A. Menzies, Andrea Parriott, Sourya Shrestha, David W. Dowdy, Ted Cohen, Joshua A. Salomon, Suzanne M. Marks, Andrew N. Hill, Carla A. Winston, Garrett R. Asay, Pennan Barry, Adam Readhead, Jennifer Flood, James G. Kahn, Priya B. Shete
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Mathematical modeling is used to understand disease dynamics, forecast trends, and inform public health prioritization. We conducted a comparative analysis of tuberculosis (TB) epidemiology and potential intervention effects in California, using three previously developed epidemiologic models of TB.
Cervical cancer screening strategies for evidence-based health care reform in China: a multicentre, open-label randomised trial
Authors: Junji Zhang, Yuqian Zhao, Yi Dai, Le Dang, Li Ma, Chunxia Yang, Yang Li, Linghua Kong, Lihui Wei, Shulan Zhang, Jihong Liu, Mingrong Xi, Long Chen, Xianzhi Duan, Qing Xiao, Guzhalinuer Abulizi, Guonan Zhang, Ying Hong, Zhenyu Zhang, Xiaohong Gao, Qi Zhou, Xing Xie, Li Li, Mayinue Niyaz, Zhifen Zhang, Jiyu Tuo, Yiling Ding, Manfei Si, Fei Chen, Li Song, Gwendolyn Zahner, Youlin Qiao, Jinghe Lang
Journal: The Lancet (2019)
CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma
Authors: Matteo Claudio Da Via', Antonio Giovanni Solimando, Andoni Garitano-Trojaola, Santiago Barrio, Nadine Rodhes, Susanne Strifler, Eva Teufel, Constantin Lapa, Hermann Einsele, Andreas Beilhack, K. Martin Kortüm
Journal: Blood (2018)